A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
par Nicolle, R;Gayet, O;Duconseil, P;Vanbrugghe, C;Roques, Julie;Bigonnet, M;Blum, Yuna;Elarouci, Nabila;Armenoult, L;Ayadi, M;de Reyniès, Aurélien;Puleo, Francesco 
;Augustin, J;Emile, J F;Svrcek, Magali;Arsenijevic, Tatjana ;Hammel, P;Giovannini, M;Grandval, P;Dahan, Laeticia;Moutardier, V;Gilabert, M;Van Laethem, Jean-Luc ;Bachet, J B;Cros, Jérôme;Iovanna, J;Dusetti, N J
Référence Annals of oncology
Publication Publié, 2020-11-01
;Augustin, J;Emile, J F;Svrcek, Magali;Arsenijevic, Tatjana ;Hammel, P;Giovannini, M;Grandval, P;Dahan, Laeticia;Moutardier, V;Gilabert, M;Van Laethem, Jean-Luc ;Bachet, J B;Cros, Jérôme;Iovanna, J;Dusetti, N JRéférence Annals of oncology
Publication Publié, 2020-11-01
Article révisé par les pairs
| Résumé : | Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of a potent stratification associated with chemotherapeutic efficacy could potentially improve prognosis by tailoring treatments. |
